Development of a new aerosol barrier mask for mitigation of spread of SARS-CoV-2 and other infectious pathogens.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
05 2021
Historique:
received: 23 02 2021
revised: 16 03 2021
accepted: 24 03 2021
pubmed: 6 4 2021
medline: 16 6 2021
entrez: 5 4 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has caused huge impact on public health and significantly changed our lifestyle. This is due to the fast airborne oro-nasal transmission of SARS-CoV-2 from the infected individuals. The generation of liquid aerosolized particles occurs when the COVID-19 patients speak, sing, cough, sneeze, or simply breathe. We have developed a novel aerosol barrier mask (ABM) to mitigate the spread of SARS-CoV-2 and other infectious pathogens. This Aerosol Barrier Mask is designed for preventing SARS-CoV-2 transmission while transporting patients within hospital facilities. This mask can constrain aerosol and droplet particles and trap them in a biofilter, while the patient is normally breathing and administrated with medical oxygen. The system can be characterized as an oxygen delivery and mitigation mask which has no unfiltered exhaled air dispersion. The mask helps to prevent the spread of SARS-CoV-2, and potentially other infectious respiratory pathogens and protects everyone in general, especially healthcare professionals.

Identifiants

pubmed: 33819714
pii: S0954-6111(21)00087-1
doi: 10.1016/j.rmed.2021.106381
pmc: PMC8007191
pii:
doi:

Substances chimiques

Aerosols 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106381

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Environ Res. 2020 Sep;188:109819
pubmed: 32569870
Lancet Infect Dis. 2020 Oct;20(10):e261-e267
pubmed: 32711692
Crit Care. 2021 Jan 8;25(1):22
pubmed: 33419456
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Pulmonology. 2020 Jul - Aug;26(4):204-212
pubmed: 32362505
Sci Rep. 2020 Nov 11;10(1):19589
pubmed: 33177563

Auteurs

Karam Abi Karam (K)

Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, Tempe, 85281, Arizona, USA.

Piyush Hota (P)

Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, Tempe, 85281, Arizona, USA; School of Engineering for Matter, Transport, and Energy, Arizona State University, Tempe, 85281, Arizona, USA.

S Jimena Mora (SJ)

Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, Tempe, 85281, Arizona, USA.

Amelia Lowell (A)

Mayo Clinic, Phoenix, 85054, Arizona, USA.

Kelly McKay (K)

Mayo Clinic, Phoenix, 85054, Arizona, USA.

Xiaojun Xian (X)

Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, Tempe, 85281, Arizona, USA.

Bhavesh Patel (B)

Mayo Clinic, Phoenix, 85054, Arizona, USA. Electronic address: patel.bhavesh@mayo.edu.

Erica Forzani (E)

Center for Bioelectronics and Biosensors, Biodesign Institute, Arizona State University, Tempe, 85281, Arizona, USA; School of Engineering for Matter, Transport, and Energy, Arizona State University, Tempe, 85281, Arizona, USA. Electronic address: eforzani@asu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH